Fibrosis stage but not NASH predicts mortality and time to development of severe liver disease in biopsy-proven NAFLD

Journal of Hepatology

Volumn 67, Issue 6, 2017, Pages 1265-1273

  Hagström, Hannes ^a,b   Nasr, Patrik ^c   Ekstedt, Mattias ^c   Hammar, Ulf ^b   Stål, Per ^a,b   Hultcrantz, Rolf ^a,b   Kechagias, Stergios ^c  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

^c LINKÖPING UNIVERSITY   (Sweden)

Author keywords

Cirrhosis; Epidemiology; Steatosis

Indexed keywords

ADULT; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DECOMPENSATED LIVER CIRRHOSIS; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; LIVER BIOPSY; LIVER CELL CARCINOMA; LIVER FAILURE; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MORBIDITY; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGNOSIS; RETROSPECTIVE STUDY; AGED; BIOPSY; LIVER; LIVER CIRRHOSIS; PATHOLOGY; TIME FACTOR;

ADULT; AGED; BIOPSY; FEMALE; HUMANS; LIVER; LIVER CIRRHOSIS; MALE; MIDDLE AGED; NON-ALCOHOLIC FATTY LIVER DISEASE; RETROSPECTIVE STUDIES; TIME FACTORS;

EID: 85030871248     PISSN: 01688278     EISSN: 16000641     Source Type: Journal    
DOI: 10.1016/j.jhep.2017.07.027     Document Type: Article

References (24)

1. Younossi, Z.M., Stepanova, M., Afendy, M., Fang, Y., Younossi, Y., Mir, H., et al. Changes in the prevalence of the most common causes of chronic liver diseases in the United States from 1988 to 2008. Clin Gastroenterol Hepatol 9 (2011), 524–530 e521.
2. Loomba, R., Sanyal, A.J., The global NAFLD epidemic. Nat Rev Gastroenterol Hepatol 10 (2013), 686–690.
3. Setiawan, V.W., Stram, D.O., Porcel, J., Lu, S.C., Le Marchand, L., Noureddin, M., Prevalence of chronic liver disease and cirrhosis by underlying cause in understudied ethnic groups: The multiethnic cohort. Hepatology 64 (2016), 1969–1977.
4. Younossi, Z.M., Koenig, A.B., Abdelatif, D., Fazel, Y., Henry, L., Wymer, M., Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology 64 (2016), 73–84.
5. Chalasani, N., Younossi, Z., Lavine, J.E., Diehl, A.M., Brunt, E.M., Cusi, K., et al. The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology 55 (2012), 2005–2023.
6. Farrell, G.C., Larter, C.Z., Nonalcoholic fatty liver disease: from steatosis to cirrhosis. Hepatology 43 (2006), S99–S112.
7. McPherson, S., Hardy, T., Henderson, E., Burt, A.D., Day, C.P., Anstee, Q.M., Evidence of NAFLD progression from steatosis to fibrosing-steatohepatitis using paired biopsies: implications for prognosis and clinical management. J Hepatol 62 (2015), 1148–1155.
8. Ekstedt, M., Franzen, L.E., Mathiesen, U.L., Thorelius, L., Holmqvist, M., Bodemar, G., et al. Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology 44 (2006), 865–873.
9. Söderberg, C., Stål, P., Askling, J., Glaumann, H., Lindberg, G., Marmur, J., et al. Decreased survival of subjects with elevated liver function tests during a 28-year follow-up. Hepatology 51 (2010), 595–602.
10. Ekstedt, M., Hagstrom, H., Nasr, P., Fredrikson, M., Stal, P., Kechagias, S., et al. Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up. Hepatology 61 (2015), 1547–1554.
11. Angulo, P., Kleiner, D.E., Dam-Larsen, S., Adams, L.A., Bjornsson, E.S., Charatcharoenwitthaya, P., et al. Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease. Gastroenterology 149 (2015), 389–397 e310.
12. Singh, S., Allen, A.M., Wang, Z., Prokop, L.J., Murad, M.H., Loomba, R., Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies. Clin Gastroenterol Hepatol 13 (2015), 643–654.
13. Cote, R.A., Robboy, S., Progress in medical information management. Systematized nomenclature of medicine (SNOMED). JAMA 243 (1980), 756–762.
14. Kleiner, D.E., Brunt, E.M., Van Natta, M., Behling, C., Contos, M.J., Cummings, O.W., et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 41 (2005), 1313–1321.
15. Bedossa, P., Poitou, C., Veyrie, N., Bouillot, J.L., Basdevant, A., Paradis, V., et al. Histopathological algorithm and scoring system for evaluation of liver lesions in morbidly obese patients. Hepatology 56 (2012), 1751–1759.
16. Bedossa, P., Utility and appropriateness of the fatty liver inhibition of progression (FLIP) algorithm and steatosis, activity, and fibrosis (SAF) score in the evaluation of biopsies of nonalcoholic fatty liver disease. Hepatology 60 (2014), 565–575.
17. Ludvigsson, J.F., Otterblad-Olausson, P., Pettersson, B.U., Ekbom, A., The Swedish personal identity number: possibilities and pitfalls in healthcare and medical research. Eur J Epidemiol 24 (2009), 659–667.
18. Ludvigsson, J.F., Andersson, E., Ekbom, A., Feychting, M., Kim, J.L., Reuterwall, C., et al. External review and validation of the Swedish national inpatient register. BMC Public Health, 11, 2011, 450.
19. Barlow, L., Westergren, K., Holmberg, L., Talback, M., The completeness of the Swedish Cancer Register: a sample survey for year 1998. Acta Oncol 48 (2009), 27–33.
20. Bottai, M., Zhang, J., Laplace regression with censored data. Biometrical J 52 (2010), 487–503.
21. Jepsen, P., Vilstrup, H., Andersen, P.K., The clinical course of cirrhosis: The importance of multistate models and competing risks analysis. Hepatology 62 (2015), 292–302.
22. Younossi, Z.M., Stepanova, M., Rafiq, N., Makhlouf, H., Younoszai, Z., Agrawal, R., et al. Pathologic criteria for nonalcoholic steatohepatitis: interprotocol agreement and ability to predict liver-related mortality. Hepatology 53 (2011), 1874–1882.
23. Dulai, P.S., Singh, S., Patel, J., Soni, M., Prokop, L.J., Younossi, Z., et al. Increased risk of mortality by fibrosis stage in non-alcoholic fatty liver disease: Systematic Review and Meta-analysis. Hepatology 65 (2017), 1557–1565.
24. Williams, C.D., Stengel, J., Asike, M.I., Torres, D.M., Shaw, J., Contreras, M., et al. Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study. Gastroenterology 140 (2011), 124–131.